SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-24-008273
Filing Date
2024-02-16
Accepted
2024-02-16 07:30:18
Documents
14
Period of Report
2024-02-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K ef20021627_8k.htm   iXBRL 8-K 26146
  Complete submission text file 0001140361-24-008273.txt   162968

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA erna-20240212.xsd EX-101.SCH 3866
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE erna-20240212_lab.xml EX-101.LAB 22547
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE erna-20240212_pre.xml EX-101.PRE 16045
16 EXTRACTED XBRL INSTANCE DOCUMENT ef20021627_8k_htm.xml XML 4233
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

IRS No.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 24645785
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)